NEK2 and primary effusion lymphoma: Because our data suggested that targeting NEK2 could be a therapeutic approach for PEL, we then compared the antitumor efficacy of JH295 treatment to that of vinblastine, a drug similar to vincristine, used clinically in PEL chemotherapeutic regimens (24).